
    
      Objectives

      Primary:

      To assess changes in [18F] fluorothymidine (FLT) uptake using Positron Emission Tomography
      (PET) following 2 weeks of Irosustat treatment in patients with early, treatment naïve,
      oestrogen receptor positive (ER +ve) breast cancer

      Secondary:

      To assess the:

        1. Pharmacodynamic profile of Irosustat

        2. Safety and tolerability of Irosustat

      Study Population: Postmenopausal women with early, treatment naïve, ER +ve breast cancer
    
  